nodes	percent_of_prediction	percent_of_DWPC	metapath
Flutamide—CYP1B1—Mitoxantrone—sarcoma	0.229	0.309	CbGbCtD
Flutamide—CYP1A1—Dacarbazine—sarcoma	0.13	0.175	CbGbCtD
Flutamide—CYP1B1—Doxorubicin—sarcoma	0.0985	0.133	CbGbCtD
Flutamide—CYP1A2—Dacarbazine—sarcoma	0.0579	0.078	CbGbCtD
Flutamide—CYP3A4—Thiotepa—sarcoma	0.0547	0.0737	CbGbCtD
Flutamide—CYP3A5—Vincristine—sarcoma	0.0415	0.0559	CbGbCtD
Flutamide—CYP3A5—Etoposide—sarcoma	0.0381	0.0513	CbGbCtD
Flutamide—CYP1A2—Etoposide—sarcoma	0.0283	0.0381	CbGbCtD
Flutamide—CYP3A4—Mitoxantrone—sarcoma	0.0235	0.0317	CbGbCtD
Flutamide—CYP3A4—Vincristine—sarcoma	0.0162	0.0218	CbGbCtD
Flutamide—CYP3A4—Etoposide—sarcoma	0.0148	0.02	CbGbCtD
Flutamide—AR—scrotum—sarcoma	0.0117	0.214	CbGeAlD
Flutamide—CYP3A4—Doxorubicin—sarcoma	0.0101	0.0136	CbGbCtD
Flutamide—AHR—myometrium—sarcoma	0.0024	0.0438	CbGeAlD
Flutamide—AHR—seminal vesicle—sarcoma	0.00217	0.0396	CbGeAlD
Flutamide—AHR—smooth muscle tissue—sarcoma	0.00182	0.0331	CbGeAlD
Flutamide—CYP1B1—mammary gland—sarcoma	0.00176	0.0321	CbGeAlD
Flutamide—AHR—cardiac atrium—sarcoma	0.00157	0.0286	CbGeAlD
Flutamide—AHR—uterus—sarcoma	0.00156	0.0284	CbGeAlD
Flutamide—AHR—tendon—sarcoma	0.00137	0.0249	CbGeAlD
Flutamide—AHR—bone marrow—sarcoma	0.00132	0.0241	CbGeAlD
Flutamide—AR—myometrium—sarcoma	0.00119	0.0216	CbGeAlD
Flutamide—Ecchymosis—Mitoxantrone—sarcoma	0.00116	0.00668	CcSEcCtD
Flutamide—Ulcer—Etoposide—sarcoma	0.00113	0.00649	CcSEcCtD
Flutamide—AHR—testis—sarcoma	0.00113	0.0206	CbGeAlD
Flutamide—CYP1B1—hematopoietic system—sarcoma	0.00107	0.0196	CbGeAlD
Flutamide—AR—seminal vesicle—sarcoma	0.00107	0.0195	CbGeAlD
Flutamide—AHR—liver—sarcoma	0.00107	0.0195	CbGeAlD
Flutamide—CYP1B1—connective tissue—sarcoma	0.00103	0.0189	CbGeAlD
Flutamide—AR—hematopoietic system—sarcoma	0.00102	0.0185	CbGeAlD
Flutamide—Transaminases increased—Epirubicin—sarcoma	0.000985	0.00566	CcSEcCtD
Flutamide—AR—connective tissue—sarcoma	0.00098	0.0179	CbGeAlD
Flutamide—Aspartate aminotransferase increased—Thiotepa—sarcoma	0.000973	0.00559	CcSEcCtD
Flutamide—Toxic epidermal necrolysis—Dactinomycin—sarcoma	0.000966	0.00555	CcSEcCtD
Flutamide—Aspartate aminotransferase increased—Dactinomycin—sarcoma	0.000966	0.00555	CcSEcCtD
Flutamide—CYP1B1—smooth muscle tissue—sarcoma	0.000947	0.0173	CbGeAlD
Flutamide—CYP2C19—hematopoietic system—sarcoma	0.000943	0.0172	CbGeAlD
Flutamide—CYP1B1—skin of body—sarcoma	0.000934	0.017	CbGeAlD
Flutamide—Transaminases increased—Doxorubicin—sarcoma	0.000912	0.00524	CcSEcCtD
Flutamide—AR—FOXA1 transcription factor network—COL18A1—sarcoma	0.0009	0.0315	CbGpPWpGaD
Flutamide—AR—smooth muscle tissue—sarcoma	0.000896	0.0163	CbGeAlD
Flutamide—AR—skin of body—sarcoma	0.000885	0.0161	CbGeAlD
Flutamide—Aspartate aminotransferase increased—Vincristine—sarcoma	0.000863	0.00496	CcSEcCtD
Flutamide—Hyperglycaemia—Thiotepa—sarcoma	0.000843	0.00484	CcSEcCtD
Flutamide—Aspartate aminotransferase increased—Mitoxantrone—sarcoma	0.00084	0.00483	CcSEcCtD
Flutamide—AHR—lymph node—sarcoma	0.000819	0.0149	CbGeAlD
Flutamide—Jaundice—Thiotepa—sarcoma	0.000812	0.00466	CcSEcCtD
Flutamide—CYP1B1—uterus—sarcoma	0.000812	0.0148	CbGeAlD
Flutamide—Herpes zoster—Epirubicin—sarcoma	0.000796	0.00457	CcSEcCtD
Flutamide—Haematuria—Thiotepa—sarcoma	0.000794	0.00456	CcSEcCtD
Flutamide—AR—cardiac atrium—sarcoma	0.000773	0.0141	CbGeAlD
Flutamide—CYP1A2—hematopoietic system—sarcoma	0.00077	0.014	CbGeAlD
Flutamide—AR—uterus—sarcoma	0.000769	0.014	CbGeAlD
Flutamide—AR—Notch-mediated HES/HEY network—TLE1—sarcoma	0.000767	0.0269	CbGpPWpGaD
Flutamide—Erectile dysfunction—Vincristine—sarcoma	0.000763	0.00438	CcSEcCtD
Flutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYOG—sarcoma	0.00076	0.0266	CbGpPWpGaD
Flutamide—CYP1A1—hematopoietic system—sarcoma	0.00076	0.0138	CbGeAlD
Flutamide—CYP1B1—lymphoid tissue—sarcoma	0.000757	0.0138	CbGeAlD
Flutamide—Photosensitivity reaction—Vincristine—sarcoma	0.000756	0.00434	CcSEcCtD
Flutamide—Erectile dysfunction—Mitoxantrone—sarcoma	0.000743	0.00427	CcSEcCtD
Flutamide—CYP3A5—hematopoietic system—sarcoma	0.000743	0.0135	CbGeAlD
Flutamide—Hepatitis—Dactinomycin—sarcoma	0.000742	0.00426	CcSEcCtD
Flutamide—Herpes zoster—Doxorubicin—sarcoma	0.000737	0.00423	CcSEcCtD
Flutamide—Hyperglycaemia—Mitoxantrone—sarcoma	0.000728	0.00418	CcSEcCtD
Flutamide—Drowsiness—Mitoxantrone—sarcoma	0.000719	0.00413	CcSEcCtD
Flutamide—AR—Notch-mediated HES/HEY network—MYOD1—sarcoma	0.000719	0.0252	CbGpPWpGaD
Flutamide—AR—lymphoid tissue—sarcoma	0.000716	0.0131	CbGeAlD
Flutamide—Liver injury—Epirubicin—sarcoma	0.000712	0.00409	CcSEcCtD
Flutamide—CYP1B1—tendon—sarcoma	0.000711	0.013	CbGeAlD
Flutamide—AR—Nongenotropic Androgen signaling—PLCG1—sarcoma	0.000709	0.0249	CbGpPWpGaD
Flutamide—Neoplasm malignant—Epirubicin—sarcoma	0.000702	0.00403	CcSEcCtD
Flutamide—Jaundice—Mitoxantrone—sarcoma	0.000701	0.00403	CcSEcCtD
Flutamide—Toxic epidermal necrolysis—Etoposide—sarcoma	0.000699	0.00401	CcSEcCtD
Flutamide—Haematuria—Mitoxantrone—sarcoma	0.000686	0.00394	CcSEcCtD
Flutamide—Jaundice cholestatic—Epirubicin—sarcoma	0.000682	0.00392	CcSEcCtD
Flutamide—AR—tendon—sarcoma	0.000674	0.0123	CbGeAlD
Flutamide—Rectal haemorrhage—Epirubicin—sarcoma	0.000664	0.00381	CcSEcCtD
Flutamide—CYP1A1—skin of body—sarcoma	0.00066	0.012	CbGeAlD
Flutamide—Liver injury—Doxorubicin—sarcoma	0.000659	0.00379	CcSEcCtD
Flutamide—Erythema—Thiotepa—sarcoma	0.000651	0.00374	CcSEcCtD
Flutamide—Neoplasm malignant—Doxorubicin—sarcoma	0.00065	0.00373	CcSEcCtD
Flutamide—Erythema—Dactinomycin—sarcoma	0.000646	0.00371	CcSEcCtD
Flutamide—Hepatitis—Mitoxantrone—sarcoma	0.000646	0.00371	CcSEcCtD
Flutamide—Tension—Thiotepa—sarcoma	0.000639	0.00367	CcSEcCtD
Flutamide—Ulcer—Epirubicin—sarcoma	0.000634	0.00364	CcSEcCtD
Flutamide—Nervousness—Thiotepa—sarcoma	0.000632	0.00363	CcSEcCtD
Flutamide—Jaundice cholestatic—Doxorubicin—sarcoma	0.000631	0.00363	CcSEcCtD
Flutamide—Rectal haemorrhage—Doxorubicin—sarcoma	0.000614	0.00353	CcSEcCtD
Flutamide—Anaemia—Thiotepa—sarcoma	0.000602	0.00345	CcSEcCtD
Flutamide—Pulmonary embolism—Epirubicin—sarcoma	0.0006	0.00344	CcSEcCtD
Flutamide—Ill-defined disorder—Dactinomycin—sarcoma	0.000599	0.00344	CcSEcCtD
Flutamide—Anaemia—Dactinomycin—sarcoma	0.000597	0.00343	CcSEcCtD
Flutamide—CYP1B1—testis—sarcoma	0.000589	0.0107	CbGeAlD
Flutamide—Ulcer—Doxorubicin—sarcoma	0.000586	0.00337	CcSEcCtD
Flutamide—Cystitis noninfective—Epirubicin—sarcoma	0.000586	0.00336	CcSEcCtD
Flutamide—Jaundice—Etoposide—sarcoma	0.000583	0.00335	CcSEcCtD
Flutamide—Leukopenia—Thiotepa—sarcoma	0.000583	0.00335	CcSEcCtD
Flutamide—Malaise—Dactinomycin—sarcoma	0.000583	0.00335	CcSEcCtD
Flutamide—AHR—Aryl Hydrocarbon Receptor Pathway—IL2—sarcoma	0.000581	0.0204	CbGpPWpGaD
Flutamide—Cystitis—Epirubicin—sarcoma	0.000579	0.00332	CcSEcCtD
Flutamide—Leukopenia—Dactinomycin—sarcoma	0.000578	0.00332	CcSEcCtD
Flutamide—CYP1A1—cardiac atrium—sarcoma	0.000577	0.0105	CbGeAlD
Flutamide—CYP1A1—uterus—sarcoma	0.000574	0.0105	CbGeAlD
Flutamide—Blood urea increased—Epirubicin—sarcoma	0.000566	0.00325	CcSEcCtD
Flutamide—AHR—Aryl Hydrocarbon Receptor Pathway—JUN—sarcoma	0.000566	0.0198	CbGpPWpGaD
Flutamide—Erythema—Mitoxantrone—sarcoma	0.000562	0.00323	CcSEcCtD
Flutamide—Hypertension—Thiotepa—sarcoma	0.000562	0.00323	CcSEcCtD
Flutamide—AHR—Integrated Breast Cancer Pathway—ATF1—sarcoma	0.000561	0.0197	CbGpPWpGaD
Flutamide—AR—testis—sarcoma	0.000558	0.0102	CbGeAlD
Flutamide—CYP3A4—hematopoietic system—sarcoma	0.000557	0.0102	CbGeAlD
Flutamide—CYP1B1—liver—sarcoma	0.000557	0.0101	CbGeAlD
Flutamide—Pulmonary embolism—Doxorubicin—sarcoma	0.000555	0.00319	CcSEcCtD
Flutamide—Anxiety—Thiotepa—sarcoma	0.000552	0.00317	CcSEcCtD
Flutamide—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—sarcoma	0.00055	0.00316	CcSEcCtD
Flutamide—Discomfort—Dactinomycin—sarcoma	0.000543	0.00312	CcSEcCtD
Flutamide—Neoplasm—Epirubicin—sarcoma	0.000542	0.00311	CcSEcCtD
Flutamide—Ecchymosis—Epirubicin—sarcoma	0.000542	0.00311	CcSEcCtD
Flutamide—Bladder pain—Epirubicin—sarcoma	0.000542	0.00311	CcSEcCtD
Flutamide—Cystitis noninfective—Doxorubicin—sarcoma	0.000542	0.00311	CcSEcCtD
Flutamide—Cystitis—Doxorubicin—sarcoma	0.000536	0.00308	CcSEcCtD
Flutamide—Confusional state—Thiotepa—sarcoma	0.000536	0.00308	CcSEcCtD
Flutamide—Anaemia—Vincristine—sarcoma	0.000533	0.00306	CcSEcCtD
Flutamide—AR—liver—sarcoma	0.000527	0.00961	CbGeAlD
Flutamide—Oedema—Dactinomycin—sarcoma	0.000527	0.00303	CcSEcCtD
Flutamide—Blood urea increased—Doxorubicin—sarcoma	0.000524	0.00301	CcSEcCtD
Flutamide—Ill-defined disorder—Mitoxantrone—sarcoma	0.000522	0.00299	CcSEcCtD
Flutamide—Thrombocytopenia—Thiotepa—sarcoma	0.00052	0.00299	CcSEcCtD
Flutamide—Anaemia—Mitoxantrone—sarcoma	0.00052	0.00298	CcSEcCtD
Flutamide—Leukopenia—Vincristine—sarcoma	0.000517	0.00297	CcSEcCtD
Flutamide—Thrombocytopenia—Dactinomycin—sarcoma	0.000516	0.00296	CcSEcCtD
Flutamide—Skin disorder—Thiotepa—sarcoma	0.000516	0.00296	CcSEcCtD
Flutamide—AHR—Aryl Hydrocarbon Receptor—SRC—sarcoma	0.000507	0.0178	CbGpPWpGaD
Flutamide—AHR—Aryl Hydrocarbon Receptor Pathway—SRC—sarcoma	0.000507	0.0178	CbGpPWpGaD
Flutamide—Malaise—Mitoxantrone—sarcoma	0.000507	0.00291	CcSEcCtD
Flutamide—Anorexia—Thiotepa—sarcoma	0.000506	0.00291	CcSEcCtD
Flutamide—Leukopenia—Mitoxantrone—sarcoma	0.000503	0.00289	CcSEcCtD
Flutamide—Anorexia—Dactinomycin—sarcoma	0.000503	0.00289	CcSEcCtD
Flutamide—Bladder pain—Doxorubicin—sarcoma	0.000502	0.00288	CcSEcCtD
Flutamide—Neoplasm—Doxorubicin—sarcoma	0.000502	0.00288	CcSEcCtD
Flutamide—Ecchymosis—Doxorubicin—sarcoma	0.000502	0.00288	CcSEcCtD
Flutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—TLE1—sarcoma	0.000501	0.0176	CbGpPWpGaD
Flutamide—Diabetes mellitus—Epirubicin—sarcoma	0.0005	0.00287	CcSEcCtD
Flutamide—Hypertension—Vincristine—sarcoma	0.000498	0.00286	CcSEcCtD
Flutamide—AHR—Aryl Hydrocarbon Receptor—VEGFA—sarcoma	0.000494	0.0173	CbGpPWpGaD
Flutamide—CYP2C19—liver—sarcoma	0.000489	0.0089	CbGeAlD
Flutamide—AHR—Aryl Hydrocarbon Receptor—NRAS—sarcoma	0.000488	0.0171	CbGpPWpGaD
Flutamide—Hypertension—Mitoxantrone—sarcoma	0.000485	0.00279	CcSEcCtD
Flutamide—Anxiety—Mitoxantrone—sarcoma	0.000477	0.00274	CcSEcCtD
Flutamide—Discomfort—Mitoxantrone—sarcoma	0.000473	0.00272	CcSEcCtD
Flutamide—AHR—Adipogenesis—FOXO1—sarcoma	0.000472	0.0166	CbGpPWpGaD
Flutamide—Somnolence—Thiotepa—sarcoma	0.000472	0.00271	CcSEcCtD
Flutamide—Oedema—Vincristine—sarcoma	0.000471	0.0027	CcSEcCtD
Flutamide—Hot flush—Epirubicin—sarcoma	0.000465	0.00267	CcSEcCtD
Flutamide—AR—Regulation of nuclear SMAD2/3 signaling—MYOD1—sarcoma	0.000465	0.0163	CbGpPWpGaD
Flutamide—Increased appetite—Epirubicin—sarcoma	0.000463	0.00266	CcSEcCtD
Flutamide—Diabetes mellitus—Doxorubicin—sarcoma	0.000463	0.00266	CcSEcCtD
Flutamide—Confusional state—Mitoxantrone—sarcoma	0.000463	0.00266	CcSEcCtD
Flutamide—Decreased appetite—Thiotepa—sarcoma	0.000462	0.00265	CcSEcCtD
Flutamide—Menopausal symptoms—Epirubicin—sarcoma	0.000461	0.00265	CcSEcCtD
Flutamide—Thrombocytopenia—Vincristine—sarcoma	0.000461	0.00265	CcSEcCtD
Flutamide—Oedema—Mitoxantrone—sarcoma	0.000459	0.00263	CcSEcCtD
Flutamide—Decreased appetite—Dactinomycin—sarcoma	0.000458	0.00263	CcSEcCtD
Flutamide—Fatigue—Thiotepa—sarcoma	0.000458	0.00263	CcSEcCtD
Flutamide—Dermatitis bullous—Epirubicin—sarcoma	0.000455	0.00261	CcSEcCtD
Flutamide—AHR—Aryl Hydrocarbon Receptor—MYC—sarcoma	0.000455	0.0159	CbGpPWpGaD
Flutamide—Fatigue—Dactinomycin—sarcoma	0.000455	0.00261	CcSEcCtD
Flutamide—Constipation—Thiotepa—sarcoma	0.000454	0.00261	CcSEcCtD
Flutamide—Thrombocytopenia—Mitoxantrone—sarcoma	0.000449	0.00258	CcSEcCtD
Flutamide—Anorexia—Vincristine—sarcoma	0.000449	0.00258	CcSEcCtD
Flutamide—Skin disorder—Mitoxantrone—sarcoma	0.000446	0.00256	CcSEcCtD
Flutamide—AHR—Aryl Hydrocarbon Receptor Pathway—EGFR—sarcoma	0.000445	0.0156	CbGpPWpGaD
Flutamide—AHR—Aryl Hydrocarbon Receptor—EGFR—sarcoma	0.000445	0.0156	CbGpPWpGaD
Flutamide—CYP1B1—Melatonin metabolism and effects—FOXO1—sarcoma	0.00044	0.0154	CbGpPWpGaD
Flutamide—Feeling abnormal—Thiotepa—sarcoma	0.000438	0.00251	CcSEcCtD
Flutamide—Anorexia—Mitoxantrone—sarcoma	0.000437	0.00251	CcSEcCtD
Flutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MITF—sarcoma	0.000437	0.0153	CbGpPWpGaD
Flutamide—CYP1B1—Estrogen Receptor Pathway—JUN—sarcoma	0.000436	0.0153	CbGpPWpGaD
Flutamide—Feeling abnormal—Dactinomycin—sarcoma	0.000434	0.00249	CcSEcCtD
Flutamide—Ill-defined disorder—Etoposide—sarcoma	0.000434	0.00249	CcSEcCtD
Flutamide—Anaemia—Etoposide—sarcoma	0.000432	0.00248	CcSEcCtD
Flutamide—Hot flush—Doxorubicin—sarcoma	0.00043	0.00247	CcSEcCtD
Flutamide—Increased appetite—Doxorubicin—sarcoma	0.000429	0.00246	CcSEcCtD
Flutamide—CYP1B1—lymph node—sarcoma	0.000427	0.00778	CbGeAlD
Flutamide—Menopausal symptoms—Doxorubicin—sarcoma	0.000427	0.00245	CcSEcCtD
Flutamide—Insomnia—Vincristine—sarcoma	0.000426	0.00245	CcSEcCtD
Flutamide—Malaise—Etoposide—sarcoma	0.000422	0.00242	CcSEcCtD
Flutamide—Dermatitis bullous—Doxorubicin—sarcoma	0.000421	0.00242	CcSEcCtD
Flutamide—AHR—Aryl Hydrocarbon Receptor—KRAS—sarcoma	0.00042	0.0147	CbGpPWpGaD
Flutamide—AHR—Integrated Breast Cancer Pathway—FOXO1—sarcoma	0.000419	0.0147	CbGpPWpGaD
Flutamide—Leukopenia—Etoposide—sarcoma	0.000418	0.0024	CcSEcCtD
Flutamide—Decreased appetite—Vincristine—sarcoma	0.000409	0.00235	CcSEcCtD
Flutamide—Somnolence—Mitoxantrone—sarcoma	0.000408	0.00234	CcSEcCtD
Flutamide—Fatigue—Vincristine—sarcoma	0.000406	0.00233	CcSEcCtD
Flutamide—AR—lymph node—sarcoma	0.000404	0.00737	CbGeAlD
Flutamide—Hypertension—Etoposide—sarcoma	0.000404	0.00232	CcSEcCtD
Flutamide—Constipation—Vincristine—sarcoma	0.000403	0.00231	CcSEcCtD
Flutamide—CYP1A2—liver—sarcoma	0.000399	0.00727	CbGeAlD
Flutamide—Decreased appetite—Mitoxantrone—sarcoma	0.000399	0.00229	CcSEcCtD
Flutamide—Fatigue—Mitoxantrone—sarcoma	0.000395	0.00227	CcSEcCtD
Flutamide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.000395	0.00227	CcSEcCtD
Flutamide—CYP1A1—liver—sarcoma	0.000394	0.00717	CbGeAlD
Flutamide—Discomfort—Etoposide—sarcoma	0.000393	0.00226	CcSEcCtD
Flutamide—Constipation—Mitoxantrone—sarcoma	0.000392	0.00225	CcSEcCtD
Flutamide—Toxic epidermal necrolysis—Epirubicin—sarcoma	0.000392	0.00225	CcSEcCtD
Flutamide—Aspartate aminotransferase increased—Epirubicin—sarcoma	0.000392	0.00225	CcSEcCtD
Flutamide—CYP3A5—liver—sarcoma	0.000385	0.00701	CbGeAlD
Flutamide—Confusional state—Etoposide—sarcoma	0.000385	0.00221	CcSEcCtD
Flutamide—Asthenia—Thiotepa—sarcoma	0.000381	0.00219	CcSEcCtD
Flutamide—Asthenia—Dactinomycin—sarcoma	0.000378	0.00217	CcSEcCtD
Flutamide—Feeling abnormal—Mitoxantrone—sarcoma	0.000378	0.00217	CcSEcCtD
Flutamide—Pruritus—Thiotepa—sarcoma	0.000376	0.00216	CcSEcCtD
Flutamide—Thrombocytopenia—Etoposide—sarcoma	0.000374	0.00215	CcSEcCtD
Flutamide—Skin disorder—Etoposide—sarcoma	0.000371	0.00213	CcSEcCtD
Flutamide—AR—Nongenotropic Androgen signaling—CREB1—sarcoma	0.000365	0.0128	CbGpPWpGaD
Flutamide—Anorexia—Etoposide—sarcoma	0.000364	0.00209	CcSEcCtD
Flutamide—Diarrhoea—Thiotepa—sarcoma	0.000363	0.00209	CcSEcCtD
Flutamide—Toxic epidermal necrolysis—Doxorubicin—sarcoma	0.000363	0.00208	CcSEcCtD
Flutamide—Aspartate aminotransferase increased—Doxorubicin—sarcoma	0.000363	0.00208	CcSEcCtD
Flutamide—Diarrhoea—Dactinomycin—sarcoma	0.000361	0.00207	CcSEcCtD
Flutamide—AHR—Aryl Hydrocarbon Receptor—HRAS—sarcoma	0.000357	0.0125	CbGpPWpGaD
Flutamide—Dizziness—Thiotepa—sarcoma	0.000351	0.00202	CcSEcCtD
Flutamide—Photosensitivity reaction—Epirubicin—sarcoma	0.000343	0.00197	CcSEcCtD
Flutamide—AHR—Adipogenesis—CREB1—sarcoma	0.000343	0.012	CbGpPWpGaD
Flutamide—Hyperglycaemia—Epirubicin—sarcoma	0.000339	0.00195	CcSEcCtD
Flutamide—Somnolence—Etoposide—sarcoma	0.000339	0.00195	CcSEcCtD
Flutamide—Asthenia—Vincristine—sarcoma	0.000338	0.00194	CcSEcCtD
Flutamide—Vomiting—Thiotepa—sarcoma	0.000338	0.00194	CcSEcCtD
Flutamide—Drowsiness—Epirubicin—sarcoma	0.000335	0.00193	CcSEcCtD
Flutamide—Vomiting—Dactinomycin—sarcoma	0.000335	0.00192	CcSEcCtD
Flutamide—Rash—Thiotepa—sarcoma	0.000335	0.00192	CcSEcCtD
Flutamide—Dermatitis—Thiotepa—sarcoma	0.000335	0.00192	CcSEcCtD
Flutamide—Headache—Thiotepa—sarcoma	0.000333	0.00191	CcSEcCtD
Flutamide—Rash—Dactinomycin—sarcoma	0.000332	0.00191	CcSEcCtD
Flutamide—Decreased appetite—Etoposide—sarcoma	0.000332	0.0019	CcSEcCtD
Flutamide—Asthenia—Mitoxantrone—sarcoma	0.000329	0.00189	CcSEcCtD
Flutamide—Fatigue—Etoposide—sarcoma	0.000329	0.00189	CcSEcCtD
Flutamide—AR—Regulation of Androgen receptor activity—FOXO1—sarcoma	0.000328	0.0115	CbGpPWpGaD
Flutamide—Jaundice—Epirubicin—sarcoma	0.000327	0.00188	CcSEcCtD
Flutamide—Constipation—Etoposide—sarcoma	0.000326	0.00187	CcSEcCtD
Flutamide—Diarrhoea—Vincristine—sarcoma	0.000322	0.00185	CcSEcCtD
Flutamide—Haematuria—Epirubicin—sarcoma	0.00032	0.00184	CcSEcCtD
Flutamide—Photosensitivity reaction—Doxorubicin—sarcoma	0.000318	0.00182	CcSEcCtD
Flutamide—Nausea—Thiotepa—sarcoma	0.000316	0.00181	CcSEcCtD
Flutamide—Feeling abnormal—Etoposide—sarcoma	0.000314	0.00181	CcSEcCtD
Flutamide—Hyperglycaemia—Doxorubicin—sarcoma	0.000314	0.0018	CcSEcCtD
Flutamide—Diarrhoea—Mitoxantrone—sarcoma	0.000314	0.0018	CcSEcCtD
Flutamide—Nausea—Dactinomycin—sarcoma	0.000313	0.0018	CcSEcCtD
Flutamide—Dizziness—Vincristine—sarcoma	0.000311	0.00179	CcSEcCtD
Flutamide—Drowsiness—Doxorubicin—sarcoma	0.00031	0.00178	CcSEcCtD
Flutamide—AHR—Integrated Breast Cancer Pathway—CREB1—sarcoma	0.000304	0.0107	CbGpPWpGaD
Flutamide—Jaundice—Doxorubicin—sarcoma	0.000302	0.00174	CcSEcCtD
Flutamide—CYP1A1—lymph node—sarcoma	0.000302	0.0055	CbGeAlD
Flutamide—Hepatitis—Epirubicin—sarcoma	0.000301	0.00173	CcSEcCtD
Flutamide—Vomiting—Vincristine—sarcoma	0.000299	0.00172	CcSEcCtD
Flutamide—AR—Notch-mediated HES/HEY network—KDR—sarcoma	0.000298	0.0105	CbGpPWpGaD
Flutamide—Rash—Vincristine—sarcoma	0.000297	0.00171	CcSEcCtD
Flutamide—Dermatitis—Vincristine—sarcoma	0.000297	0.0017	CcSEcCtD
Flutamide—Oedema peripheral—Epirubicin—sarcoma	0.000297	0.0017	CcSEcCtD
Flutamide—Haematuria—Doxorubicin—sarcoma	0.000296	0.0017	CcSEcCtD
Flutamide—Headache—Vincristine—sarcoma	0.000295	0.00169	CcSEcCtD
Flutamide—Vomiting—Mitoxantrone—sarcoma	0.000292	0.00167	CcSEcCtD
Flutamide—Rash—Mitoxantrone—sarcoma	0.000289	0.00166	CcSEcCtD
Flutamide—Dermatitis—Mitoxantrone—sarcoma	0.000289	0.00166	CcSEcCtD
Flutamide—CYP3A4—liver—sarcoma	0.000289	0.00526	CbGeAlD
Flutamide—Headache—Mitoxantrone—sarcoma	0.000287	0.00165	CcSEcCtD
Flutamide—Nausea—Vincristine—sarcoma	0.00028	0.00161	CcSEcCtD
Flutamide—Hepatitis—Doxorubicin—sarcoma	0.000279	0.0016	CcSEcCtD
Flutamide—Oedema peripheral—Doxorubicin—sarcoma	0.000274	0.00158	CcSEcCtD
Flutamide—Asthenia—Etoposide—sarcoma	0.000274	0.00157	CcSEcCtD
Flutamide—Nausea—Mitoxantrone—sarcoma	0.000272	0.00156	CcSEcCtD
Flutamide—CYP1A1—Melatonin metabolism and effects—FOXO1—sarcoma	0.000271	0.0095	CbGpPWpGaD
Flutamide—Pruritus—Etoposide—sarcoma	0.00027	0.00155	CcSEcCtD
Flutamide—CYP1A1—Estrogen Receptor Pathway—JUN—sarcoma	0.000268	0.00941	CbGpPWpGaD
Flutamide—CYP3A5—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000265	0.00929	CbGpPWpGaD
Flutamide—Erythema—Epirubicin—sarcoma	0.000262	0.0015	CcSEcCtD
Flutamide—Diarrhoea—Etoposide—sarcoma	0.000261	0.0015	CcSEcCtD
Flutamide—Tension—Epirubicin—sarcoma	0.000257	0.00148	CcSEcCtD
Flutamide—Nervousness—Epirubicin—sarcoma	0.000255	0.00146	CcSEcCtD
Flutamide—Dizziness—Etoposide—sarcoma	0.000252	0.00145	CcSEcCtD
Flutamide—AHR—Integrated Breast Cancer Pathway—MDM2—sarcoma	0.000251	0.00881	CbGpPWpGaD
Flutamide—AHR—Adipogenesis—CTNNB1—sarcoma	0.000244	0.00857	CbGpPWpGaD
Flutamide—Ill-defined disorder—Epirubicin—sarcoma	0.000243	0.0014	CcSEcCtD
Flutamide—Vomiting—Etoposide—sarcoma	0.000243	0.00139	CcSEcCtD
Flutamide—Erythema—Doxorubicin—sarcoma	0.000242	0.00139	CcSEcCtD
Flutamide—Anaemia—Epirubicin—sarcoma	0.000242	0.00139	CcSEcCtD
Flutamide—AHR—Circadian rythm related genes—CREB1—sarcoma	0.000242	0.00847	CbGpPWpGaD
Flutamide—Rash—Etoposide—sarcoma	0.000241	0.00138	CcSEcCtD
Flutamide—Dermatitis—Etoposide—sarcoma	0.00024	0.00138	CcSEcCtD
Flutamide—Headache—Etoposide—sarcoma	0.000239	0.00137	CcSEcCtD
Flutamide—Tension—Doxorubicin—sarcoma	0.000238	0.00137	CcSEcCtD
Flutamide—Malaise—Epirubicin—sarcoma	0.000236	0.00136	CcSEcCtD
Flutamide—Nervousness—Doxorubicin—sarcoma	0.000236	0.00135	CcSEcCtD
Flutamide—AR—Nongenotropic Androgen signaling—SRC—sarcoma	0.000235	0.00825	CbGpPWpGaD
Flutamide—Leukopenia—Epirubicin—sarcoma	0.000235	0.00135	CcSEcCtD
Flutamide—AR—Regulation of nuclear SMAD2/3 signaling—FOXO1—sarcoma	0.000233	0.00818	CbGpPWpGaD
Flutamide—Nausea—Etoposide—sarcoma	0.000227	0.0013	CcSEcCtD
Flutamide—Hypertension—Epirubicin—sarcoma	0.000226	0.0013	CcSEcCtD
Flutamide—Ill-defined disorder—Doxorubicin—sarcoma	0.000225	0.00129	CcSEcCtD
Flutamide—Anaemia—Doxorubicin—sarcoma	0.000224	0.00129	CcSEcCtD
Flutamide—Anxiety—Epirubicin—sarcoma	0.000222	0.00128	CcSEcCtD
Flutamide—CYP2C19—Melatonin metabolism and effects—FOXO1—sarcoma	0.000222	0.00777	CbGpPWpGaD
Flutamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.000222	0.00127	CcSEcCtD
Flutamide—Discomfort—Epirubicin—sarcoma	0.00022	0.00127	CcSEcCtD
Flutamide—AHR—Integrated Breast Cancer Pathway—CCND1—sarcoma	0.000219	0.00768	CbGpPWpGaD
Flutamide—Malaise—Doxorubicin—sarcoma	0.000219	0.00126	CcSEcCtD
Flutamide—AHR—Integrated Breast Cancer Pathway—JUN—sarcoma	0.000219	0.00766	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.000218	0.00763	CbGpPWpGaD
Flutamide—Leukopenia—Doxorubicin—sarcoma	0.000217	0.00125	CcSEcCtD
Flutamide—AHR—Integrated Breast Cancer Pathway—CTNNB1—sarcoma	0.000217	0.0076	CbGpPWpGaD
Flutamide—AR—Androgen receptor signaling pathway—FOXO1—sarcoma	0.000216	0.00759	CbGpPWpGaD
Flutamide—Confusional state—Epirubicin—sarcoma	0.000216	0.00124	CcSEcCtD
Flutamide—Oedema—Epirubicin—sarcoma	0.000214	0.00123	CcSEcCtD
Flutamide—Thrombocytopenia—Epirubicin—sarcoma	0.000209	0.0012	CcSEcCtD
Flutamide—Hypertension—Doxorubicin—sarcoma	0.000209	0.0012	CcSEcCtD
Flutamide—Skin disorder—Epirubicin—sarcoma	0.000208	0.00119	CcSEcCtD
Flutamide—Anxiety—Doxorubicin—sarcoma	0.000206	0.00118	CcSEcCtD
Flutamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.000205	0.00118	CcSEcCtD
Flutamide—CYP2C19—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000205	0.00718	CbGpPWpGaD
Flutamide—Discomfort—Doxorubicin—sarcoma	0.000204	0.00117	CcSEcCtD
Flutamide—Anorexia—Epirubicin—sarcoma	0.000204	0.00117	CcSEcCtD
Flutamide—Confusional state—Doxorubicin—sarcoma	0.0002	0.00115	CcSEcCtD
Flutamide—AR—FOXA1 transcription factor network—JUN—sarcoma	0.000198	0.00695	CbGpPWpGaD
Flutamide—Oedema—Doxorubicin—sarcoma	0.000198	0.00114	CcSEcCtD
Flutamide—AR—Regulation of Androgen receptor activity—MDM2—sarcoma	0.000197	0.00689	CbGpPWpGaD
Flutamide—Thrombocytopenia—Doxorubicin—sarcoma	0.000194	0.00111	CcSEcCtD
Flutamide—Insomnia—Epirubicin—sarcoma	0.000193	0.00111	CcSEcCtD
Flutamide—Skin disorder—Doxorubicin—sarcoma	0.000192	0.0011	CcSEcCtD
Flutamide—AHR—Integrated Breast Cancer Pathway—VEGFA—sarcoma	0.000191	0.00669	CbGpPWpGaD
Flutamide—Somnolence—Epirubicin—sarcoma	0.00019	0.00109	CcSEcCtD
Flutamide—AR—Integrated Breast Cancer Pathway—ATF1—sarcoma	0.00019	0.00666	CbGpPWpGaD
Flutamide—Anorexia—Doxorubicin—sarcoma	0.000189	0.00108	CcSEcCtD
Flutamide—Decreased appetite—Epirubicin—sarcoma	0.000186	0.00107	CcSEcCtD
Flutamide—Fatigue—Epirubicin—sarcoma	0.000184	0.00106	CcSEcCtD
Flutamide—Constipation—Epirubicin—sarcoma	0.000183	0.00105	CcSEcCtD
Flutamide—CYP1B1—Tryptophan metabolism—MDM2—sarcoma	0.000182	0.0064	CbGpPWpGaD
Flutamide—Insomnia—Doxorubicin—sarcoma	0.000179	0.00103	CcSEcCtD
Flutamide—Feeling abnormal—Epirubicin—sarcoma	0.000176	0.00101	CcSEcCtD
Flutamide—Somnolence—Doxorubicin—sarcoma	0.000176	0.00101	CcSEcCtD
Flutamide—AHR—Integrated Breast Cancer Pathway—MYC—sarcoma	0.000176	0.00616	CbGpPWpGaD
Flutamide—AHR—Circadian rythm related genes—JUN—sarcoma	0.000174	0.00609	CbGpPWpGaD
Flutamide—CYP1A2—Melatonin metabolism and effects—FOXO1—sarcoma	0.000173	0.00605	CbGpPWpGaD
Flutamide—Decreased appetite—Doxorubicin—sarcoma	0.000172	0.000988	CcSEcCtD
Flutamide—AHR—Integrated Breast Cancer Pathway—EGFR—sarcoma	0.000172	0.00602	CbGpPWpGaD
Flutamide—CYP1A2—Estrogen Receptor Pathway—JUN—sarcoma	0.000171	0.006	CbGpPWpGaD
Flutamide—AR—Regulation of Androgen receptor activity—JUN—sarcoma	0.000171	0.00599	CbGpPWpGaD
Flutamide—Fatigue—Doxorubicin—sarcoma	0.000171	0.00098	CcSEcCtD
Flutamide—AR—Regulation of nuclear SMAD2/3 signaling—CREB1—sarcoma	0.000169	0.00593	CbGpPWpGaD
Flutamide—Constipation—Doxorubicin—sarcoma	0.000169	0.000972	CcSEcCtD
Flutamide—AR—Nongenotropic Androgen signaling—HRAS—sarcoma	0.000166	0.00581	CbGpPWpGaD
Flutamide—Feeling abnormal—Doxorubicin—sarcoma	0.000163	0.000937	CcSEcCtD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor Pathway—IL2—sarcoma	0.000163	0.00572	CbGpPWpGaD
Flutamide—AHR—Integrated Breast Cancer Pathway—KRAS—sarcoma	0.000162	0.00569	CbGpPWpGaD
Flutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—sarcoma	0.000159	0.00558	CbGpPWpGaD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor Pathway—JUN—sarcoma	0.000159	0.00556	CbGpPWpGaD
Flutamide—AR—Androgen receptor signaling pathway—CREB1—sarcoma	0.000157	0.0055	CbGpPWpGaD
Flutamide—Asthenia—Epirubicin—sarcoma	0.000153	0.000881	CcSEcCtD
Flutamide—AR—Regulation of Androgen receptor activity—SRC—sarcoma	0.000153	0.00537	CbGpPWpGaD
Flutamide—AR—Coregulation of Androgen receptor activity—CCND1—sarcoma	0.000153	0.00537	CbGpPWpGaD
Flutamide—AR—Coregulation of Androgen receptor activity—CTNNB1—sarcoma	0.000152	0.00531	CbGpPWpGaD
Flutamide—Pruritus—Epirubicin—sarcoma	0.000151	0.000869	CcSEcCtD
Flutamide—Diarrhoea—Epirubicin—sarcoma	0.000146	0.00084	CcSEcCtD
Flutamide—AHR—Integrated Breast Cancer Pathway—TP53—sarcoma	0.000144	0.00506	CbGpPWpGaD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor—SRC—sarcoma	0.000142	0.00499	CbGpPWpGaD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor Pathway—SRC—sarcoma	0.000142	0.00499	CbGpPWpGaD
Flutamide—Asthenia—Doxorubicin—sarcoma	0.000142	0.000815	CcSEcCtD
Flutamide—AR—Integrated Breast Cancer Pathway—FOXO1—sarcoma	0.000142	0.00497	CbGpPWpGaD
Flutamide—Dizziness—Epirubicin—sarcoma	0.000141	0.000812	CcSEcCtD
Flutamide—Pruritus—Doxorubicin—sarcoma	0.00014	0.000804	CcSEcCtD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor—VEGFA—sarcoma	0.000139	0.00486	CbGpPWpGaD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor—NRAS—sarcoma	0.000137	0.0048	CbGpPWpGaD
Flutamide—Vomiting—Epirubicin—sarcoma	0.000136	0.000781	CcSEcCtD
Flutamide—Diarrhoea—Doxorubicin—sarcoma	0.000135	0.000778	CcSEcCtD
Flutamide—Rash—Epirubicin—sarcoma	0.000135	0.000774	CcSEcCtD
Flutamide—Dermatitis—Epirubicin—sarcoma	0.000135	0.000774	CcSEcCtD
Flutamide—Headache—Epirubicin—sarcoma	0.000134	0.000769	CcSEcCtD
Flutamide—Dizziness—Doxorubicin—sarcoma	0.000131	0.000752	CcSEcCtD
Flutamide—AR—Androgen receptor signaling pathway—MDM2—sarcoma	0.00013	0.00455	CbGpPWpGaD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor—MYC—sarcoma	0.000128	0.00447	CbGpPWpGaD
Flutamide—Nausea—Epirubicin—sarcoma	0.000127	0.00073	CcSEcCtD
Flutamide—Vomiting—Doxorubicin—sarcoma	0.000126	0.000723	CcSEcCtD
Flutamide—Rash—Doxorubicin—sarcoma	0.000125	0.000717	CcSEcCtD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor Pathway—EGFR—sarcoma	0.000125	0.00437	CbGpPWpGaD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor—EGFR—sarcoma	0.000125	0.00437	CbGpPWpGaD
Flutamide—Dermatitis—Doxorubicin—sarcoma	0.000125	0.000716	CcSEcCtD
Flutamide—Headache—Doxorubicin—sarcoma	0.000124	0.000712	CcSEcCtD
Flutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—sarcoma	0.000123	0.00432	CbGpPWpGaD
Flutamide—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000123	0.00432	CbGpPWpGaD
Flutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—sarcoma	0.000123	0.00431	CbGpPWpGaD
Flutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CTNNB1—sarcoma	0.000122	0.00428	CbGpPWpGaD
Flutamide—AR—Regulation of nuclear SMAD2/3 signaling—JUN—sarcoma	0.000122	0.00427	CbGpPWpGaD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor—KRAS—sarcoma	0.000118	0.00413	CbGpPWpGaD
Flutamide—Nausea—Doxorubicin—sarcoma	0.000118	0.000675	CcSEcCtD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	0.000115	0.00405	CbGpPWpGaD
Flutamide—AHR—Circadian rythm related genes—TP53—sarcoma	0.000115	0.00402	CbGpPWpGaD
Flutamide—AR—Androgen receptor signaling pathway—CCND1—sarcoma	0.000113	0.00397	CbGpPWpGaD
Flutamide—AR—Androgen receptor signaling pathway—JUN—sarcoma	0.000113	0.00396	CbGpPWpGaD
Flutamide—CYP1A1—Tryptophan metabolism—MDM2—sarcoma	0.000112	0.00394	CbGpPWpGaD
Flutamide—AR—Androgen receptor signaling pathway—CTNNB1—sarcoma	0.000112	0.00393	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—CREB1—sarcoma	0.000103	0.00361	CbGpPWpGaD
Flutamide—AR—Androgen receptor signaling pathway—SRC—sarcoma	0.000101	0.00355	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—sarcoma	0.0001	0.00352	CbGpPWpGaD
Flutamide—AR—SIDS Susceptibility Pathways—CREB1—sarcoma	0.0001	0.00351	CbGpPWpGaD
Flutamide—CYP1B1—Aryl Hydrocarbon Receptor—HRAS—sarcoma	0.0001	0.00351	CbGpPWpGaD
Flutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—sarcoma	9.88e-05	0.00346	CbGpPWpGaD
Flutamide—AR—Regulation of nuclear SMAD2/3 signaling—MYC—sarcoma	9.79e-05	0.00343	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—sarcoma	9.77e-05	0.00342	CbGpPWpGaD
Flutamide—AR—Gene Expression—FUS—sarcoma	9.06e-05	0.00318	CbGpPWpGaD
Flutamide—AR—Androgen receptor signaling pathway—EGFR—sarcoma	8.88e-05	0.00311	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—SRC—sarcoma	8.76e-05	0.00307	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—SRC—sarcoma	8.76e-05	0.00307	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—sarcoma	8.53e-05	0.00299	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	8.52e-05	0.00299	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—MDM2—sarcoma	8.51e-05	0.00298	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—NRAS—sarcoma	8.43e-05	0.00296	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—MYC—sarcoma	7.85e-05	0.00275	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—sarcoma	7.68e-05	0.00269	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—sarcoma	7.68e-05	0.00269	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—CCND1—sarcoma	7.41e-05	0.0026	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—JUN—sarcoma	7.4e-05	0.00259	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—CTNNB1—sarcoma	7.34e-05	0.00257	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—sarcoma	7.26e-05	0.00254	CbGpPWpGaD
Flutamide—AR—SIDS Susceptibility Pathways—JUN—sarcoma	7.21e-05	0.00253	CbGpPWpGaD
Flutamide—CYP1A2—Tryptophan metabolism—MDM2—sarcoma	7.17e-05	0.00251	CbGpPWpGaD
Flutamide—AR—SIDS Susceptibility Pathways—CTNNB1—sarcoma	7.15e-05	0.00251	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	7.05e-05	0.00247	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—VEGFA—sarcoma	6.46e-05	0.00227	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—sarcoma	6.4e-05	0.00224	CbGpPWpGaD
Flutamide—AR—SIDS Susceptibility Pathways—VEGFA—sarcoma	6.3e-05	0.00221	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—sarcoma	6.23e-05	0.00218	CbGpPWpGaD
Flutamide—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—sarcoma	6.17e-05	0.00216	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	6.14e-05	0.00215	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	6.13e-05	0.00215	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	6.08e-05	0.00213	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—MYC—sarcoma	5.95e-05	0.00208	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—EGFR—sarcoma	5.82e-05	0.00204	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—sarcoma	5.59e-05	0.00196	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—SRC—sarcoma	5.59e-05	0.00196	CbGpPWpGaD
Flutamide—CYP3A4—Tryptophan metabolism—MDM2—sarcoma	5.53e-05	0.00194	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	5.5e-05	0.00193	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—KRAS—sarcoma	5.49e-05	0.00193	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—sarcoma	5.44e-05	0.00191	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—sarcoma	5.38e-05	0.00188	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	5.35e-05	0.00188	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—sarcoma	5.01e-05	0.00176	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	4.93e-05	0.00173	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—sarcoma	4.9e-05	0.00172	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—sarcoma	4.9e-05	0.00172	CbGpPWpGaD
Flutamide—AR—Integrated Breast Cancer Pathway—TP53—sarcoma	4.88e-05	0.00171	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	4.82e-05	0.00169	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—sarcoma	4.63e-05	0.00162	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	4.55e-05	0.0016	CbGpPWpGaD
Flutamide—AR—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	4.05e-05	0.00142	CbGpPWpGaD
Flutamide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—sarcoma	3.93e-05	0.00138	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—ENO2—sarcoma	3.01e-05	0.00105	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—HBA1—sarcoma	2.99e-05	0.00105	CbGpPWpGaD
Flutamide—CYP1B1—Metabolism—PLCG1—sarcoma	2.55e-05	0.000895	CbGpPWpGaD
Flutamide—AR—Generic Transcription Pathway—MYC—sarcoma	2.45e-05	0.000858	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—ENO2—sarcoma	1.96e-05	0.000687	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—HBA1—sarcoma	1.95e-05	0.000683	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—ENO2—sarcoma	1.85e-05	0.000649	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—HBA1—sarcoma	1.84e-05	0.000645	CbGpPWpGaD
Flutamide—CYP3A5—Metabolism—PLCG1—sarcoma	1.66e-05	0.000583	CbGpPWpGaD
Flutamide—CYP1A1—Metabolism—PLCG1—sarcoma	1.57e-05	0.000551	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—ENO2—sarcoma	1.52e-05	0.000531	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—HBA1—sarcoma	1.51e-05	0.000528	CbGpPWpGaD
Flutamide—CYP2C19—Metabolism—PLCG1—sarcoma	1.29e-05	0.000451	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—ENO2—sarcoma	1.18e-05	0.000414	CbGpPWpGaD
Flutamide—AR—Gene Expression—MYC—sarcoma	1.18e-05	0.000413	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—HBA1—sarcoma	1.17e-05	0.000411	CbGpPWpGaD
Flutamide—CYP1A2—Metabolism—PLCG1—sarcoma	1e-05	0.000351	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—ENO2—sarcoma	9.11e-06	0.00032	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—HBA1—sarcoma	9.06e-06	0.000317	CbGpPWpGaD
Flutamide—CYP3A4—Metabolism—PLCG1—sarcoma	7.73e-06	0.000271	CbGpPWpGaD
